Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London
EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) — Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing…
Category: Globenewswire
LightSolver to Unveil the First Public Demonstration of its All-Optical Computer at SC26
LightSolver to present its Boeing corrosion-simulation work and join Birds of a Feather (BoF) session on analog computing at the…
Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board
Appointment brings leadership experience building and financing biopharma companies AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) — Filana Therapeutics, Inc.…
Lycia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) — Lycia Therapeutics, Inc. (Nasdaq: LYCA), a clinical-stage biotechnology company focused…
Dyne Therapeutics to Participate in Upcoming Investor Conference
WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional…
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and…
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing Expanding…
Applied Biologics Announces Research Collaboration with Dartmouth College Focused on Computational Protein Engineering
Formal collaboration with Dartmouth’s Thayer School of Engineering will advance computationally guided therapeutic protein design supporting Applied Biologics’ gene therapy…
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions…
CHARM Therapeutics and Collaborator Dr. Florian Perner to Present Compelling Data Showing the Potential of Next-Generation Menin Inhibitors to Deliver More Durable Responses for AML at the 8th ASH Annual Meeting
LONDON – 11 November 2026 — CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage biotechnology company addressing resistance in acute myeloid…